M Cazzola Selected Research

Chronic Obstructive Pulmonary Disease (COPD)

10/2008	Novel long-acting bronchodilators for COPD and asthma.
02/2008	Outcomes for COPD pharmacological trials: from lung function to biomarkers.
02/2006	Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD.
12/2004	The functional impact of adding salmeterol and tiotropium in patients with stable COPD.
01/2004	Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.
05/2003	Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD.
05/2003	A single high dose of formoterol is as effective as the same dose administered in a cumulative manner in patients with acute exacerbation of COPD.
01/2003	Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD.
10/2002	Acute effects of higher than customary doses of salmeterol and salbutamol in patients with acute exacerbation of COPD.
06/2002	Addition of an extra dose of salmeterol Diskus to conventional dose of salmeterol Diskus in patients with COPD.
04/2002	Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease.
03/2002	Bronchodilating effect of oxitropium bromide in heart disease patients with exacerbations of COPD: double-blind, randomized, controlled study.
11/2001	Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD.
08/2001	Pulmonary disposition of lomefloxacin in patients with acute exacerbation of chronic obstructive pulmonary disease. A multiple-dose study.
01/2001	Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD.
01/2001	Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease.
12/2000	Additive effects of salmeterol and fluticasone or theophylline in COPD.
01/2000	Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist.

Articles by Research Topic

Disease

18	Chronic Obstructive Pulmonary Disease (COPD) 10/2008 - 01/2000
4	Asthma (Bronchial Asthma) 10/2008 - 06/2000
2	Respiratory Tract Infections (Respiratory Tract Infection) 06/2006 - 10/2005
1	Heart Diseases (Heart Disease) 03/2002
1	Airway Obstruction (Choking) 01/2002
1	Hypersensitivity (Allergy) 08/2001
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2001
1	Rheumatoid Arthritis 09/2000
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/2000
1	Chronic Bronchitis 06/2000
1	Hemochromatosis (Bronze Diabetes) 04/2000

Drug/Important Bio-Agent (IBA)

8	formoterol (Oxis)FDA Link 02/2006 - 01/2001
6	salmeterol (Serevent)FDA Link 12/2004 - 12/2000
3	Budesonide (Pulmicort)FDA LinkGeneric 02/2006 - 05/2003
3	Albuterol (Salbutamol)FDA LinkGeneric 10/2002 - 01/2002
2	Bronchodilator Agents (Bronchodilators)IBA 10/2008 - 01/2003
2	fluticasone (Cutivate)FDA LinkGeneric 05/2003 - 12/2000
2	zafirlukast (Accolate)FDA Link 01/2001 - 01/2000
1	Biological Markers (Surrogate Marker)IBA 02/2008
1	telithromycin (Ketek)FDA Link 06/2006
1	GasesIBA 02/2006
1	Azithromycin (Zithromax)FDA LinkGeneric 10/2005
1	tiotropium (Spiriva)FDA Link 12/2004
1	oxitropium (oxitropium bromide)IBA 03/2002
1	lomefloxacin (Maxaquin)FDA Link 08/2001
1	Air Pollutants (Pollutants, Air)IBA 08/2001
1	AllergensIBA 08/2001
1	Interferon-alpha (Interferon Alfa)FDA Link 01/2001
1	Theophylline (Theon)FDA LinkGeneric 12/2000
1	nebivolol FDA Link 11/2000
1	Celiprolol (ST1396)IBA 11/2000
1	Collagen Type II (Type II Collagen)IBA 09/2000
1	Cefaclor (Ceclor)FDA LinkGeneric 06/2000
1	MacrolidesIBA 06/2000
1	IronIBA 04/2000

Therapy/Procedure

1	Nebulizers and Vaporizers (Inhaler) 01/2004
1	Metered Dose Inhalers (Metered Dose Inhaler) 04/2002
1	Drug Therapy (Chemotherapy) 08/2000